GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » Shiller PE Ratio

Ampio Pharmaceuticals (Ampio Pharmaceuticals) Shiller PE Ratio : (As of May. 25, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ampio Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Ampio Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals Shiller PE Ratio Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ampio Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Ampio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ampio Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's Shiller PE Ratio falls into.



Ampio Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ampio Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Ampio Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.48/129.4194*129.4194
=-2.480

Current CPI (Dec. 2023) = 129.4194.

Ampio Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -69.000 99.695 -89.573
201406 -51.000 100.560 -65.637
201409 -54.000 100.428 -69.589
201412 -57.000 99.070 -74.462
201503 -42.000 99.621 -54.563
201506 -42.000 100.684 -53.987
201509 -42.000 100.392 -54.144
201512 -60.000 99.792 -77.813
201603 -39.000 100.470 -50.237
201606 -30.000 101.688 -38.181
201609 -21.000 101.861 -26.682
201612 -18.000 101.863 -22.870
201703 -9.000 102.862 -11.324
201706 -12.000 103.349 -15.027
201709 -18.000 104.136 -22.370
201712 -195.000 104.011 -242.635
201803 81.000 105.290 99.563
201806 -9.000 106.317 -10.956
201809 -6.000 106.507 -7.291
201812 27.000 105.998 32.966
201903 -15.000 107.251 -18.101
201906 1.063 108.070 1.273
201909 -15.000 108.329 -17.920
201912 -12.000 108.420 -14.324
202003 -12.000 108.902 -14.261
202006 -6.000 108.767 -7.139
202009 -6.000 109.815 -7.071
202012 -6.000 109.897 -7.066
202103 -6.000 111.754 -6.948
202106 -6.000 114.631 -6.774
202109 -5.800 115.734 -6.486
202112 -13.000 117.630 -14.303
202203 -9.200 121.301 -9.816
202206 -6.600 125.017 -6.832
202209 -10.060 125.227 -10.397
202212 -3.440 125.222 -3.555
202303 -5.200 127.348 -5.285
202306 -1.800 128.729 -1.810
202309 -1.530 129.860 -1.525
202312 -2.480 129.419 -2.480

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ampio Pharmaceuticals  (OTCPK:AMPE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ampio Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ampio Pharmaceuticals (Ampio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
373 Inverness Parkway, Suite 200, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Michael A Martino director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes director 640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka officer: Chief Operating Officer C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely officer: CFO 4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow officer: Chief Operating Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso director C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles director 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or director, officer: Chief Scientific Officer C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift officer: Chief Regulatory Affairs 807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor officer: Chief Financial Officer 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111

Ampio Pharmaceuticals (Ampio Pharmaceuticals) Headlines

From GuruFocus

Ampio Pharmaceuticals Reports First-Quarter Financial Results

By PRNewswire PRNewswire 07-05-2022